LUCD Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 bal. 2024 @ 23:00):

Stats
Dzisiejszy wolumen	275 028
Średni wolumen	174 998
Kapitalizacja rynkowa	36.22M
EPS	$-0.250 ( 2024-03-26 )
Następna data zysków	( $-0.270 ) 2024-06-20
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.600
ATR14	$0.00500 (0.67%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-22	White Debra	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sparks Ronald M	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Lapidus Stanley	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Cox James L	Buy	150 000	Employee stock option (right to buy)
2024-02-22	Sokolov Jacque J	Buy	150 000	Employee stock option (right to buy)

INSIDER POWER
33.30
Last 57 transactions
Buy: 13 183 319 \| Sell: 4 158 892

Wolumen Korelacja

Długi: 0.04 (neutral)

Krótki: -0.53 (weak negative)

Signal:(59.269) Neutral

Lucid Diagnostics Inc. Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Lucid Diagnostics Inc. Korelacja - Waluta/Towar

0.33
( neutral )

0.56
( weak )

0.00
( neutral )

0.86
( strong )

0.47
( neutral )

Lucid Diagnostics Inc. Finanse

Annual	2023
Przychody:	$2.43M
Zysk brutto:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2023
Przychody:	$2.43M
Zysk brutto:	$-6.05M (-249.18 %)
EPS:	$-1.260

FY	2022
Przychody:	$377 000
Zysk brutto:	$-3.24M (-858.62 %)
EPS:	$-1.550

FY	2021
Przychody:	$500 000
Zysk brutto:	$-85 000.00 (-17.00 %)
EPS:	$-1.510

Financial Reports:

No articles found.

Lucid Diagnostics Inc.

Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.